Obesity evidence dossier
Survodutide
A glucagon-containing incretin now with confirmatory Phase 3 obesity efficacy (16.6% at 76 weeks, efficacy estimand). Liver-fat and visceral-fat signals disproportionate to weight loss may differentiate it, and the CVOT MACE readout is a near-term catalyst.
Total weight loss
13.0%
SYNCHRONIZE-1 · 6 mg weekly · week 76 · Includes treatment stops
Placebo-adjusted
7.6%
Difference from placebo in the same study when reported.
Study context
GLP-1/glucagon receptor agonist/Adults with obesity or overweight, without diabetes/725 participants across the study/76-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
SYNCHRONIZE-1 · 6 mg weekly · 76 weeks
Adults with obesity or overweight, without diabetes. 725 participants across the study (not this dose arm alone).
Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment.
- Average weight loss
- 13%
- Placebo group
- 5.4% loss
- Beyond placebo
- 7.6 percentage points (arm subtraction)
- 95% confidence interval, total loss
- 11.6–14.4%
- Stopped due to adverse events
- Not verified for this result
Score: 70% × 53.2 total-loss points + 30% × 38.0 beyond-placebo points = 49/100, rounded. Conversion scales
SYNCHRONIZE-1, NEJM ↗Phase 3 · Journal article · Reviewed 2026-09-21
Evidence
Benchmark read
SYNCHRONIZE-1: Includes treatment stops.
Diabetes data
The diabetes and MASH programs should be read separately because baseline disease changes the benchmark.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Gastrointestinal adverse events were common, especially during titration.
Main cautions
Not approved; full Phase 3 safety, discontinuation, and estimand detail should be reviewed. Diabetes (SYNCHRONIZE-2) and MASLD cohorts must be read separately.
Upcoming catalyst
What to watch next
Remaining SYNCHRONIZE Phase 3 readouts through 2026 and SYNCHRONIZE-CVOT MACE topline expected late 2026.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06077864
Phase 3
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim
Non-diabetic obesity
Apr 2, 2026
NCT06309992
Phase 3
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight
Boehringer Ingelheim
Non-diabetic obesity
Mar 13, 2026
NCT06214741
Phase 3
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
Boehringer Ingelheim
Non-diabetic obesity
Feb 4, 2026
NCT06176365
Phase 3
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
Boehringer Ingelheim
Non-diabetic obesity
Dec 12, 2025
NCT04667377
Phase 2
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
Boehringer Ingelheim
Non-diabetic obesity
Nov 2, 2023
NCT07407348
Phase 1
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim
Non-diabetic obesity
Mar 17, 2026
NCT05202353
Phase 1
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Boehringer Ingelheim
Non-diabetic obesity
Jan 30, 2026
NCT06745284
Phase 1
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Boehringer Ingelheim
Non-diabetic obesity
Sep 30, 2025
NCT06564441
Phase 1
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
Boehringer Ingelheim
Non-diabetic obesity
Mar 13, 2026
NCT06200467
Phase 1
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
Boehringer Ingelheim
Non-diabetic obesity
Mar 13, 2026
NCT06492135
Phase 1
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
Boehringer Ingelheim
Non-diabetic obesity
Apr 23, 2025
NCT05896384
Phase 1
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
Boehringer Ingelheim
Non-diabetic obesity
Apr 16, 2025